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Abstract
Growth hormone (GH) inhibits fat accumulation and promotes protein accretion, therefore the fall in GH observed with weight
gain and normal aging may contribute to metabolic dysfunction. To directly test this hypothesis a novel mouse model of adult
onset-isolated GH deficiency (AOiGHD) was generated by cross breeding rat GH promoter-driven Cre recombinase mice (Cre)
with inducible diphtheria toxin receptor mice (iDTR) and treating adult Cre+/2,iDTR+/2 offspring with DT to selectively destroy
the somatotrope population of the anterior pituitary gland, leading to a reduction in circulating GH and IGF-I levels. DT-treated
Cre2/2,iDTR+/2 mice were used as GH-intact controls. AOiGHD improved whole body insulin sensitivity in both low-fat and
high-fat fed mice. Consistent with improved insulin sensitivity, indirect calorimetry revealed AOiGHD mice preferentially
utilized carbohydrates for energy metabolism, as compared to GH-intact controls. In high-fat, but not low-fat fed AOiGHD
mice, fat mass increased, hepatic lipids decreased and glucose clearance and insulin output were impaired. These results
suggest the age-related decline in GH helps to preserve systemic insulin sensitivity, and in the context of moderate caloric
intake, prevents the deterioration in metabolic function. However, in the context of excess caloric intake, low GH leads to
impaired insulin output, and thereby could contribute to the development of diabetes.
Citation: Luque RM, Lin Q, Co´rdoba-Chaco´n J, Subbaiah PV, Buch T, et al. (2011) Metabolic Impact of Adult-Onset, Isolated, Growth Hormone Deficiency
(AOiGHD) Due to Destruction of Pituitary Somatotropes. PLoS ONE 6(1): e15767. doi:10.1371/journal.pone.0015767
Editor: Toshi Shioda, Massachusetts General Hospital, United States of America
Received September 24, 2010; Accepted November 26, 2010; Published January 19, 2011
This is an open-access article distributed under the terms of the Creative Commons Public Domain declaration which stipulates that, once placed in the public
domain, this work may be freely reproduced, distributed, transmitted, modified, built upon, or otherwise used by anyone for any lawful purpose.
Funding: This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development Merit Award and
NIH AG-031465 (to RDK); Grants from Programa Ramon y Cajal RYC-2007-00186, Programa Jose Castillejo JC2008-00220 and BFU2008-01136/BFI del Ministerio de
Educacio´n y Ciencia e Innovacion (to RML) and Fondo de Investigacio´n sanitaria del ISCIII FI06/00804 (to JCC), Spain; NIH HL68585 and DK78165 (to PVS); Fund for
Scientific Research (F.W.O.)-Flanders (Belgium) and the Research Fund of the K.U.Leuven (to HV). The funders had no role in study design, data collection and
analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: Kineman@uic.edu
Introduction
Circulating growth hormone (GH) and insulin-like growth
factor I (IGF-I) levels steadily rise after birth, plateau around
puberty, then decline thereafter at a rate of ,14% for every
decade of life [1]. GH levels also decline with weight gain,
independent of age [2]. Since GH has both lipolytic and anabolic
properties [3], it is hypothesized that the decline in GH with age
and weight gain is in part responsible for the progression of
metabolic disease. Therefore, multiple studies have been conduct-
ed to examine the impact of GH replacement in elderly and obese
individuals [4–6] and off-label use and abuse of GH is becoming
more prevalent in healthy adults to enhance body image and
athletic performance. However, the true impact of age and weight-
related alterations in endogenous GH levels on adult health and
disease remains to be clarified, because the bulk of our knowledge
is based on studies of 1) short-term GH administration in normal
subjects, 2) prolonged GH excess due to GH-producing pituitary
tumors, 3) developmental GHD, that might not reflect the
consequences of GH decline after sexual maturation and 4) adult
onset GHD (AOGHD) due to pituitary surgery or head trauma,
which is frequently accompanied by other pituitary defects,
making it difficult to determine what changes are due specifically
to GH loss. For these reasons, this report describes the
development and characterization of a mouse model of adult-
onset, isolated GHD (AOiGHD), where experiments were
conducted to determine the impact of AOiGHD on whole body
insulin sensitivity and glucose tolerance, body composition and
circulating and hepatic fat accumulation. Results revealed a partial
reduction in endogenous GH levels has both positive and negative
effects on metabolic function depending on nutritional status.
Materials and Methods
Ethics Statement
This study was carried out in strict accordance with the
recommendations in the Guide for the Care and Use of
Laboratory Animals of the National Institutes of Health. The
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protocol was approved by the Institutional Animal Care and Use
Committees of Jesse Brown VA Medical Center (Protocol #07-06
and 10-03) and the University of Illinois at Chicago (Protocol
#07-036 and 09-246). All surgeries were performed under
isoflurane anesthesia and tail vein blood samples were taken after
application of anesthetic cream (2.5% lidocaine, 2.5% prolocaine).
Animals
A mouse model of AOiGHD was generated by crossbreeding
rat GH promoter driven Cre-recombinase (Cre) mice [7] to
inducible monkey diphtheria-toxin receptor (iDTR) mice [8], both
in a C57BL/6 background (Fig. 1A). Mice heterozygous for
iDTR, with (Cre+/2,iDTR+/2) and without (Cre2/2,iDTR+/2)
Cre-recombinase, were treated with DT between 10–12wks of age
either by multiple ip injections (4ng/g BW, 26/day for 10d), or by
continuous low dose delivery via osmotic pumps (6ng/h for 7d),
where pumps were surgically placed and removed under isoflurane
anesthesia. Mice were maintained on a standard rodent chow diet
(fat, 17 kcal%; carbohydrate, 56 kcal%; protein 27 kcal% -
Formulab Diet, Purina Mills, Inc., Richmond, IN) or fed a low fat
diet (LF: fat, 10% kcal%; carbohydrate, 70 kcal%; protein, 20
kcal% - Research Diets, New Brunswick, NJ) starting at 4 weeks of
age, where a subset of mice were switched to a high fat diet fat
(HF: fat, 45% kcal; carbohydrate, 35 kcal%; protein 20 kcal% -
Research Diets), immediately following DT treatment.
Pituitary phenotype
Pituitary cell cultures or paraffin embedded pituitary sections
were processed for immunocytochemistry as previously described
[7] using rabbit polyclonal antibodies, directed against rat GH,
mouse PRL, human ACTH, rat TSH ß-subunit, or rat LH ß-
subunit (Dr. A.F. Parlow, NHPP,NIDDK). In addition, specificity
of DT-mediated cell destruction was tested by treating pituitary cell
cultures prepared from Cre2/2,iDTR+/2 and Cre+/2,iDTR+/2
mice (200,000-cells/well, 3-wells/cultured) with DT (10ng/ml) for
12h. Cells were washed 36, cultured for an additional 24h and
total RNA extracted for assessment of GH and PRL mRNA levels
as described below.
mRNA analysis
Total RNA was extracted from tissues or pituitary cell cultures,
reversed transcribed and amplified by quantitative real-time PCR
[7]. Primer sequences, Genbank accession numbers and product
sizes are provided as supplemental information (Table-S3). In
studies examining the impact of DT on pituitary GH, liver IGF-I
and hypothalamic GHRH mRNA levels, data was adjusted by
cyclophilin-A mRNA levels, to control for variations in the
amount of RNA used and efficiency of the RT reaction. In studies
evaluating the impact of DT on expression of hormones in whole
pituitaries taken from LF and HF fed mice, the expression of some
housekeeping genes varied with diet, therefore the mRNA copy
number for the transcript of interest was adjusted by a
normalization factor (NF) calculated from the mRNA copy
number of three separate housekeeping genes (glyceraldehyde-3-
phosphate dehydrogenase, hypoxanthine ribosyltransferase and
cyclophilin-A) using the GeNorm 3.3 program [9].
Circulating hormones and metabolites
GH, IGF-I, insulin, leptin, corticosterone, testosterone, thyroid
hormone (T4) and prolactin levels were assessed using ELISA kits.
Triglycerides, NEFA and cholesterol levels were determined using
reagents and microtiter plate procedures from WAKO Diagnos-
tics. Blood glucose was assessed by glucometer (OneTouch,
SureStep, Johnson & Johnson, Milpitas, CA).
Liver lipid analysis
Liver was homogenized in PBS containing protease inhibitors
and an aliquot extracted according to the method of Bligh and
Dyer [10]. Lipids were resuspended in 0.1% Triton-X 100 in PBS
and aliquots were assessed for triglycerides. H&E stained liver
sections were also compared between groups for the amount of
unstained intracellular space within hepatocytes, indicative of lipid
accumulation.
In vivo evaluation of metabolic status
Glucose tolerance tests were performed after an overnight fast
and insulin tolerance tests were performed under ad libitum fed
conditions between 0800h–1100h. Blood was collected at t0, for
hormone and nutrient measurements, as described above.
Assessment of respiratory metabolism (O2 consumption/CO2
production), food and water intake, activity and rearing measure-
ments were performed in house using the PHYSIOCAGE system
and METABOLISM analysis software (Panlab Harvard Appara-
tus, Barcelona, Spain). Whole body composition was assessed by
NMR (MiniSpec LF50, Bruker Optics, Manning Park, Billerica
MA).
Statistics
Student’s t-tests were used to evaluate the impact of DT on GH-
axis function in Cre+/2,DTR+/2 and Cre2/2,DTR+/2 mice.
Comparison of the effect of genotype and diet on circulating
hormones, tissue mRNA transcript levels, response to GTT and
ITT was assessed by ANOVA, followed by Newman Keul’s post-
hoc test. For data collected from the PHYSIOCAGE system, the
average day and night VO2, VCO2 and EE and the cumulative
food and water intake (24h) and activity levels (day or night) from
two consecutive light cycles were compared between genotype,
within diet, by student’s t-test. RQs collected over a 48h period
were pooled for each group and used to calculate the percent
relative cumulative frequency (PRCF), as previously described [11]
where statistical comparisons were based on the 50th percentile
values and curve slopes.
Results
Development and characterization of the AOiGHD model
Cre+/2,iDTR+/2 mice express DTR only in the pituitary
(Fig. 1B), due to somatotrope-specific, Cre-mediated excision of
the floxed STOP cassette 59 of the iDTR transgene. In the absence
of DT, expression of DTR did not impact somatotrope
morphology and number (Fig. 1C–D), growth, GH/IGF-I
output or metabolic function (Fig.S1). However, when adult
Cre+/2,iDTR+/2 mice (10–12wks) are treated with DT there is a
dramatic reduction in the size of the anterior pituitary gland,
compared to DT-treated Cre2/2,iDTR+/2 controls, where
morphology of the DT-treated Cre2/2,iDTR+/2 controls were
identical to that of untreated Cre2/+,iDTR+/2 (Fig. 1C) and WT
mice (data not shown). Reduced pituitary size was associated with
a reduction in the proportion of GH-producing cells, GH mRNA
and circulating GH (Fig. 1C,II and Fig. 1D), as well as a
reduction in liver IGF-I mRNA and circulating IGF-I (Fig. 1E).
However, the DT-mediated decline in GH was not proportional to
the ,90% reduction in somatotrope numbers. This discrepancy
may be explained by reduced negative feedback of GH/IGF-I at
the level of the hypothalamus and pituitary. This hypothesis is
consistent with the fact that the few remaining somatotropes in
DT-treated Cre+/2,DTR+/2 pituitaries are hypertrophied and
intensely GH immunopositive (Fig. 1C,III and Fig.S2), and
hypothalamic expression of GHRH is increased (Fig. 1F).
Impact of AOiGHD on Mouse Metabolic Function
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Figure 1. Design and validation of the AOiGHD mouse model. (A) rGHp-Cre and iDTR transgenic mice were crossbred to generate mice that
express the DTR in the GH-producing cells (somatotropes) of the anterior pituitary gland, (B) Analysis of DTR mRNA copy number in pituitary (PIT),
pancreas (PAN), liver (LIV) and adipose tissue (FAT) from Cre+/2,DTR+/2 mice (without DT treatment) reveals that DTR is expressed only in the pituitary
(other tissues tested [but not shown] were muscle, spleen, brain, lung, kidney, skin, intestine, adrenal, testis, ovary), ‘‘No RT PIT’’ indicates PCR
amplification of total pituitary mRNA which was not reversed transcribed. The tissue specific pattern of DTR mRNA matched that previously reported
for Cre recombinase mRNA in rGHp-Cre Tg mice [7]. Cre+/2,DTR+/2 mice are normal until treated with DT, which results in the destruction of the
somatotrope population. (C) Gross morphology (I) and GH immunofluorescence of pituitary cross-sections (II) and enzymatically dispersed pituitary
cells (III) from DT-treated Cre2/2,DTR+/2 mice (controls, left panels) and DT-treated Cre+/2,DTR+/2 mice (AOiGHD, right panels). GH immuno-positive
cells appear red and cell nuclei appear blue (II and III). Somatotropes from DT treated Cre+/2,DTR+/2 mice are enlarged, relative to DT treated controls
(III arrows). (D) Percentage of GH immuno-positive cells in pituitaries from DT-treated Cre2/2,iDTR+/2 mice and vehicle (V)- and DT-treated
Cre+/2,DTR+/2 mice (left), and pituitary GH mRNA (middle) and circulating GH (right), in DT-treated control and AOiGHD mice. (E) Liver IGF-I mRNA
(left) and circulating total IGF-I (right). (F) Hypothalamic expression of GHRH. Analysis of circulating hormones and tissue expression analysis were
conducted 7 months post DT treatment. Hormone mRNA copy numbers were adjusted by HPRT mRNA copy number to control for total RNA reverse
transcribed and the efficiency of the reaction. (G) Impact of in vitro vehicle- (V) and DT-treatment (10ng/ml for 24h) on GH and prolactin mRNA levels
Impact of AOiGHD on Mouse Metabolic Function
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Nonetheless, these compensatory mechanisms are not sufficient to
maintain normal levels of GH/IGF-I.
Since a subpopulation of lactotropes arise from somatotropes
during pituitary development [7], some lactotropes could express
DTR and be sensitive to DT-mediated destruction. However the
destructive impact of DT on lactotropes appears to be minimal
since treatment of Cre+/2,DTR+/2 pituitary cells with DT did not
significantly alter prolactin mRNA, but did dramatically reduce
GH mRNA levels when compared to DT-treated Cre2/2,
DTR+/2 cultures (Fig. 1G). Also, in vivo DT treatment did not
negatively affect the appearance of the other pituitary cell types
(Fig. S2A). To confirm that the functional capacity of the other
pituitary cell types was not altered, circulating levels of prolactin,
testosterone, T4 and corticosterone were measured in DT-treated
Cre+/2,iDTR+/2 mice and found to not differ from controls
(Table-1). In addition, the time to conception and litter size of
DT-treated Cre+/2,DTR+/2 male or female mice bred to
wildtype-controls, did not differ from that observed using
wildtype-C57Bl/6 mice (Table-S1). Finally, all of the DT-treated
Cre+/2,DTR+/2 female mice successfully cared for their litters
and pup weight at weaning did not differ from control litters.
Taken together these results indicate lactotropes, gonadotropes,
thyrotropes and corticotropes are not overtly altered by somato-
trope destruction, thus confirming DT-treated, Cre+/2,DTR+/2
adult mice are appropriate models of AOiGHD.
AOiGHD alters metabolic function
For initial studies, male mice were group housed and provided
standard rodent chow (17% total kcal from fat). At 10wk of age,
DT was administered by multiple injections, as originally reported
[8]. Body weight increased from 2m to 7m post-DT treatment in
both AOiGHD and GH-intact controls, but did not differ due to
GH status, within age (Fig. 2A). However, AOiGHD mice had
relatively more fat-mass, compared to controls (Fig. 2B), with
significant differences in subcutaneous and retroperitoneal depots.
Enhanced fat-mass was associated with an increase in circulating
leptin (Fig. 2C). The increase in fat-mass was confirmed in a
separate set of AOiGHD mice, using whole body NMR (p=0.04,
Fig. 2D), and this increase was associated with a decrease in lean-
mass (p = 0.08). After 7m of AOiGHD, there was a small but
highly significant reduction in liver weight (Fig. 2B). In contrast,
the absolute and relative weight of kidneys, spleen and testis were
not significantly altered (data not shown). Despite the increase in
fat-mass, AOiGHD mice (2–3m post-DT) displayed a modest
improvement in the response to insulin and glucose, with
significant differences at 15min post-injection (Fig. 2E). The fact
that AOiGHD mice also had reduced glucose and insulin levels
7m post-DT (Fig. 2F) suggests improved insulin sensitivity persists
with age.
In the next series of experiments, modifications were made to
the protocol in order to 1) decrease animal to animal variation, 2)
limit the nonspecific toxic effects of bolus DT-treatment and 3)
better model a ‘‘western’’ diet. Specifically, all experimental mice
were generated by breeding female rGHpCre+/2 mice to male
iDTR+/+ mice and litter size was standardized to 6–8 pups/litter
72h after parturition, based on evidence that early nutritional
status can dramatically impact adult metabolic and GH-axis
function [12]. Mice were weaned at 3wks of age, placed on a low
fat (LF, 10% total kcal from fat) diet at 4wks and single housed at
6wks. The rationale to switch all mice to a LF diet at an early age
is based on the fact that even with standard chow feeding, C57Bl/
6 mice quickly gain fat-mass at variable rates, which may
mask effects of AOiGHD. As adults, Cre+/2,DTR+/2 and
Cre2/2,iDTR+/2 male mice were treated with a low, continuous
dose of DT via subcutaneous, osmotic minipump, and half of the
mice were switched to a high fat diet (HF, 45% total kcal from fat).
The experimental paradigm is illustrated in Fig. 3A, along with
body weight changes over time.
Circulating GH and IGF-I, and pituitary expression of GH
were reduced in DT-treated Cre+/2,DTR+/2 mice in both diet
groups (Fig. 3B). In contrast to the suppression of GH/IGF-I in
DT-treated Cre+/2,DTR+/2 mice, expression of the other
pituitary hormones (POMC, glycoprotein hormone a-subunit,
and ß-subunits of TSH, FSH and LH) were significantly elevated,
while there was a small but significant reduction in prolactin
mRNA levels in DT-treated Cre+/2,DTR+/2 mice (Fig.S2,B).
However, circulating prolactin and testosterone did not differ
between control and AOiGHD mice within diet (Fig.S2,B).
These observations, taken together with our initial findings (Fig. 1
and Table-1), indicate that somatotrope depletion persists with
age in DT-treated Cre+/2,DTR+/2 mice, while other pituitary cell
types remain relatively intact and functional. However, it should
be noted that independent of GH-status, HF-feeding significantly
suppressed pituitary GH mRNA levels (Fig. 3B) and testosterone
levels (Fig.S2,B), while enhancing circulating IGF-I levels
(Fig. 3B), as previously reported [13–15]. Therefore, the
metabolic impact of GHD in high-fat mice should be considered
in the context of altered testosterone and IGF-I levels.
Body weights of LF-fed AOiGHD and GH-intact control mice
did not significantly differ up to 12m of age (Fig. 3A). However,
body weights of HF-fed AOiGHD mice were significantly less than
HF-fed controls. Since mice continue to grow after puberty (albeit
at a slower rate), the differences observed in the HF-fed groups
may be related to the combined effects of low GH and testosterone
in AOiGHD mice, where both hormones are required for optimal
skeletal and muscle growth [16]. Relative fat-depot and liver
Table 1. Circulating levels (ng/ml) of pituitary (regulated)
hormones, in AOiGHD and Controls.
Males* Females
Control AOiGHD Control AOiGHD
Prolactin 1.7560.27 1.660.13 43.1166.8 34.1163.25
Testosterone 7.4262.78 5.4261.76 ND ND
Thyroid hormone
(T4)
5.4260.22 5.5160.13 6.7860.24 7.6460.45
Corticosterone fed 1.3860.25 1.4160.25 2.8660.85 3.8660.59
Corticosterone
fasted
3462.09 33.863.22 33.3365.7 32.3864.32
*Values shown for males are from LF- fed mice described in Fig 3
(from t0 samples of GTT or ITT), while female values are from chow
fed mice. Hormone levels were compared between genotypes from
blood samples taken at the same age, from 2–6 months post DT
treatment (n =6–12 samples/measurement).
doi:10.1371/journal.pone.0015767.t001
in primary pituitary cell cultures from adult Cre2/2,DTR+/2 and Cre+/2,DTR+/2 mice, where values are the means of 3 independent experiments.
Panels C–F represent data collected after 2 months post-DT treatment with n = 8–12 mice/group. Asterisks indicate values that differ from controls,
*, p,0.05, ** p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0015767.g001
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weight (assessed at 12m) did not differ due to GH status in LF-fed
mice. In contrast, relative fat-depot weight was increased and liver
weight decreased in HF-fed AOiGHD mice compared to controls
(Fig. 3C), a relationship similar to that observed in younger
AOiGHD mice fed a standard chow diet (Fig. 2B). The decrease
in liver weight in HF-fed AOiGHD mice was associated with
decrease in liver triglycerides (Fig. 3C), without changes in
circulating triglycerides, NEFA or cholesterol (Table-S2). Exam-
ination of H&E stained liver sections from AOiGHD and control
mice fed a standard chow diet revealed less unstained area in
AOiGHD hepatocytes, indicative of reduced fat accumulation
(Fig.S3).
To evaluate the interaction of AOiGHD and diet on glucose
homeostasis, ITT and GTT were performed at 5–6m post-DT
(Fig. 4A). Fed and fasted glucose levels were increased in response
to HF diet but were not altered by GH-status (Table-S2). The
response to GTT did not differ between LF-fed, AOiGHD and
control mice, while response to ITT was significantly improved
(Fig. 4A, and AUC based on absolute glucose levels (mg/dl);
controls 138196635 vs. AOiGHD 120216459, p,0.02) and this
was associated with a significant reduction in fed and fasted insulin
levels (Fig. 4B).
HF-feeding impaired insulin-mediated glucose clearance in both
control and AOiGHD mice (AUC, LF-controls 138196635 vs.
HF-controls 163916808 [p,0.05] and LF-AOiGHD 120216459
vs. HF-AOiGHD 148936829 [p,0.05]). However, in both HF-
and LF-fed mice, glucose levels remained significantly lower in
AOiGHD mice at the later time points following insulin injection
(Fig. 4A). Despite these differences in insulin sensitivity, the
response to GTT deteriorated in HF-fed AOiGHD mice relative
to controls (Fig. 4A, AUC HF-controls 3639862835 vs. HF-
AOiGHD 4304661590, p,0.05). These differences may be
attributed to the fact that the compensatory rise in insulin was
blunted in HF-fed AOiGHD mice, resulting in a significant
difference in insulin levels between AOiGHD and controls, under
fasted and fed conditions (Fig. 4B). These results suggest that
GH/IGF-I may be important in maintaining ß cell function,
which is supported by the observation that the level of whole
Figure 2. Impact of 2 to 7 months of AOiGHD on metabolic endpoints in male mice fed a standard rodent chow diet. (A) Body weights
(B) Relative fat depot (subcutaneous [SC], urogenital [UG], retroperitoneal [RP]) and liver (LIV) weight, of DT-treated Cre+/2,DTR+/2 (AOiGHD) mice
compared to DT-treated Cre2/2,DTR+/2 controls set at 1. (C) Serum leptin levels measured 2 months post DT treatment in DT-treated Cre2/2,DTR+/2
and vehicle-treated Cre+/2,DTR+/2 mice (controls [ctrl]), compared to AOiGHD mice. (D) Percent total body weight of free fluid, fat and lean tissue
weight measured by whole body NMR 2.5 months post DT treatment, using the MiniSpec LF50 (Bruker Optics, Germany). (E) Insulin tolerance tests
(ITT, 0.75U/kg ip) and glucose tolerance tests (GTT, 2g/kg ip) conducted 2–3 months post DT treatment. (F) Glucose and insulin levels measured in
serum samples (trunk blood) 7 month post DT treatment. Values are means +/2 SEM, of n = 8–12 mice/group. Asterisks indicate values which
significantly differ from controls, * p,0.05, *** P,0.001. a, indicates a significant effect of age (p,0.05), independent of GH status. Data presented in
panels A–B and E–F are from AOiGHD and littermate controls, where DT was delivered by multiple ip injections, while data shown in panel D is from a
separate set of mice (2.5 months post-DT treatment), where DT was delivered by osmotic minipump as described in Fig. 3. It should be noted that
these metabolic endpoints did not differ between Cre+/2,DTR+/2 and Cre2/2,DTR+/2 mice not treated with DT, as shown in Fig. S1.
doi:10.1371/journal.pone.0015767.g002
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pancreatic INS-2 mRNA, the primary transcript contributing to
circulating insulin in mice, was significantly suppressed by
AOiGHD (Fig. 4C).
To further evaluate the impact of AOiGHD, whole body
metabolic function was evaluated by indirect calorimetry and
activity level and food/water intake was monitored. The overall
respiratory quotient (RQ) of LF-fed AOiGHD was significantly
elevated compared to LF-fed controls (Fig. 5A–B, middle panels;
note right shift in the percent relative cumulative frequency
distribution [PRCF] of RQs, 50th percentile LF-controls RQ
0.829 vs. LF-AOiGHD RQ 0.893, p,0.001) and this difference
was more pronounced during the absorptive state (night-time
feeding). As illustrated in Fig. 5C, the increase in RQ in LF-fed
AOiGHD mice was associated with a significant decrease in
nocturnal VO2 and energy expenditure (EE), without significant
changes in VCO2. These changes were not associated with
significant alterations in mean activity levels (Fig. 5D) or food
intake (Fig. 5E). Interestingly, LF-fed, AOiGHD mice drank less
water than controls, which may be related to changes in body
composition or due to changes in cardiovascular/renal function
(Fig. 5E). HF-feeding reduced the RQ in both control (50th
percentile RQ 0.796) and AOiGHD (50th percentile RQ 0.819)
mice (Fig. 5A–B, bottom panels) and blunted the dynamic diurnal
rhythms in RQ typically observed in LF-fed mice, as illustrated by
the steeper slopes of PRCF curves in HF- vs. LF-fed mice. Despite
this reduction, the overall RQ remained significantly higher
(p,0.05) in AOiGHD mice, as compared to controls. Independent
of GH-status, HF feeding also decreased activity, increased the
amount of calories consumed, but had no effect on the mass
(grams) of food consumed, while decreasing water intake (Fig.S4),
as previously reported by other laboratories [17,18].
Discussion
AOiGHD improves whole body insulin sensitivity
These studies reveal AOiGHD is associated with both positive
and negative effects on metabolic function depending on age and
diet. Common across age and diet was the observation that
AOiGHD improved whole body insulin sensitivity. These findings
are consistent with the improved insulin sensitivity reported in
developmental GHD and GH insensitive (GHRKO) mice [19–
21], but are in contrast to the majority of clinical studies showing
adults with GHD are insulin resistant [22–24]. These apparent
species differences may be more related to diet, lifestyle,
environmental factors and/or etiology and specificity of GHD,
based on the finding that a rural Brazilian family with isolated
GHD due to an inactivating mutation in the GHRH-R, were also
found to be more insulin sensitive, as compared to their normal
counterparts [25,26]. In addition adult patients with Laron
syndrome (inactivating mutations in the GH receptor) remained
relatively insulin sensitive (calculated by HOMA-IR), despite an
obese phenotype [27]. Finally, adult patients with both GHD and
type-I diabetes were shown to require less insulin to normalize
glucose and therefore suffered from more frequent hypoglycemic
Figure 3. Optimized paradigm to generate AOiGHDmice and compare the impact of a high fat and low fat diet. (A) Growth curves, (B)
Circulating GH and IGF-I levels (from t0 GTT samples, Fig. 3A) and pituitary GH mRNA (copy number/0.05mg total RNA adjusted by a normalization
factor of 3 separate housekeeping genes, see methods for details). (C) Fat depot (combined subcutaneous, urogenital and retroperitoneal fat pads)
and liver weights adjusted by body weight and liver triglyceride content (mg/g tissue weight). Asterisks indicate values which significantly differ from
controls, * p,0.05, ** p,0.01, *** P,0.001. ‘‘a’’ indicates significant impact of diet, independent of GH status (p,0.05). Values are means +/2 SEM of
n = 12–17 mice/group.
doi:10.1371/journal.pone.0015767.g003
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events, and these features were normalized after GH therapy [28].
Improved insulin signaling in the context of isolated GHD is
consistent with the well accepted anti-insulin actions of GH
following an acute bolus injection in normal and GHD adults [29],
and as observed following chronic GH elevation in patients with
GH producing pituitary tumors [30], as well as in mice
overexpressing GH [21].
The exact mechanism by which GH reduces insulin sensitivity
remains to be clarified. However, since GH promotes fat breakdown,
it is hypothesized that FFA play a role in GH-mediated insulin
resistance. This hypothesis is supported by the observation that the
anti-insulin actions of short-term GH treatment are blunted by the
anti-lipolytic agent, acipimox [31]. However, in the current study
circulating NEFA and triglyceride levels were not altered by GH
status, indicating GH-mediated changes in insulin sensitivity can
occur, independent of changes in circulating lipids. Our results are
consistent with reports showing GH-mediated insulin resistance
occurs in liver-specific IGF-I knockout (LID) mice, which have a 75%
reduction in circulating IGF-I levels leading to a 3–4 fold increase in
GH, with no significant alteration in circulating FFA levels [32]. Also
LID mice crossed with GHR antagonist transgenic mice were shown
to have improved insulin sensitivity despite elevated FFA levels [32].
Finally, a lipid-independent effect of GH on insulin signaling is
suggested by a clinical study showing GH-treatment of GHD, type I
diabetics suppressed insulin sensitivity in the presence or absence of
heparin infusion [33]. In vitro studies also support a direct inhibitory
effect of GH on insulin signaling in adipocytes [21,34].
The observation that AOiGHDmice exhibited an increase in the
RQ, without significant alterations in food intake and activity level,
indicates carbohydrates are being preferentially utilized for cellular
metabolism, consistent with improved insulin sensitivity. A negative
relationship between GH and carbohydrate utilization has also been
observed in GH-treated, healthy or GHD subjects [35,36]. Of note,
the difference in RQ between AOiGHD and GH-intact mice was
most prominent during the evening hours when mice are actively
feeding, while mean values for each group steadily converged
throughout the day, a time when mice are sleeping (voluntary ‘fast’).
Although the rise in GH observed with fasting, which occurs in mice
[37] as well as humans, is thought to contribute to a shift in nutrient
availability and utilization, the diurnal pattern of RQ in AOiGHD
indicates a prolonged reduction in circulating GH levels can also
have a profound impact on whole body metabolism in the
absorptive state. The limited impact of GHD in the post-absorptive
state may be related to the dramatic diurnal patterns in adrenal
function reported in mice, where glucocorticoids levels peak at the
end of the light phase [38], which may mask any impact of GHD on
peripheral insulin sensitivity.
AOiGHD impairs diet-induced compensatory insulin
output
In order for glucose tolerance to remain constant when whole body
insulin sensitivity changes, a reciprocal alteration in insulin output has
to occur, which is indeed the case in LF-fed AOiGHD mice which
show improved insulin sensitivity and low insulin levels under both
fed and fasted conditions. However, HF-fed AOiGHD exhibit
impaired glucose clearance, despite improved insulin sensitivity,
where circulating insulin levels and whole pancreatic INS-2 transcript
remained inappropriately low, compared to GH-intact controls.
These observations strongly suggest GH/IGF-I is important in
maintaining ß-cell function in the adult, a role only previously
recognized in mouse models of developmental global and pancreatic
GH insensitivity [20,39,40]. A direct stimulatory effect of GH on ß-
cell function is further supported by the observations that islets do
express GHR [41,42] and GH stimulates ß–cell proliferation and
insulin release in normal human islet cultures [43] and protects
against inflammatory cytokine-induced apoptosis in ß-cell lines,
where these actions require STAT5 activation [44]. There are also
isolated clinical studies suggesting GH may support ß-cell function.
Specifically, GHD patients display impaired 1st phase insulin release
during a hyperglycemic clamp [45] and 30 months of low dose GH
replacement improved insulin output in response to oral GTT 3-fold
compared to the pre-GH response [46]. Consistent with these
observations, non-diabetic acromegalics were shown to have an
exaggerated insulin response to glucose stimulation [47]. Admittedly,
in clinical trials it is difficult to determine if GH-associated changes in
insulin output are direct or due to GH-mediated changes in insulin
sensitivity, however these observations coupled with our current
findings showing AOiGHD have lower circulating insulin levels in
both fed and fasted conditions and reduced pancreatic expression of
INS-2, independent of diet, support a role for GH in maintaining
adult ß-cell function. It remains to be explored whether this effect is
due to changes in ß-cell number and/or amount of insulin produced/
cell and if the impact of AOiGHD is mediated by a direct or indirect
mechanisms, perhaps via reduction in systemic or local production of
IGF-I.
Figure 4. Impact of AOiGHD and diet on glucose homeostasis.
(A) Insulin tolerance tests (ITT, 1U/kg ip, top panels) and glucose
tolerance tests (GTT, 1g/kg ip, bottom panels) in LF (left panels) and HF
(right panels) fed AOiGHD (solid lines) and control (dotted lines) mice,
performed at 5–6 months post DT treatment. (B) Insulin levels under
fed and fasted (overnight) conditions, measured from tail vein blood
samples collected at t0 in ITT and GTT, respectively. (C) Insulin-2 mRNA
levels (copy number/0.05 mg total RNA adjusted by a normalization
factor of 3 separate housekeeping genes, see methods for details).
Asterisks indicate values which significantly differ from controls,
* p,0.05, ** p,0.01. Values are means +/2 SEM, of n = 8–17 mice/
group.
doi:10.1371/journal.pone.0015767.g004
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AOiGHD increases fat depot weight but decreases liver
weight and TG content
As observed in humans with AOGHD [2,45], AOiGHD mice
have relatively more fat, compared to GH-intact controls.
However these differences were only observed in mice fed a
standard chow or HF diet, but not in mice provided a LF diet.
Interestingly, an opposite effect of AOiGHD was observed on liver
weight and TG content of HF-fed mice, suggesting when calories
are in excess they are preferentially stored in adipose tissue
reserves, reducing accumulation in the liver, a shift that may be
explained at least in part by enhanced insulin sensitivity. Although
further studies are required to determine if AOiGHD differentially
Figure 5. Indirect calorimetry, activity and food/water intake. (A) 48h profiles of respiratory quotient (RQ = VCO2 (ml/min/kg0.75) / VO2 (ml/
min/kg0.75) where data was pooled from two separate runs using different mice in each run (n = 10 mice/group total). Comparisons were first made
between LF- and HF-fed control mice to verify the accuracy of the gas monitoring system (top panel, 4 months post DT treatment), then AOiGHD
mice were compared to controls within diet (LF, 5 months post DT treatment [middle panel] and HF, 5.5 months post DT-treatment [bottom panel]).
(B) Percent relative cumulative frequency of 48h RQ values was calculated as reported by Riachi et al [11], and 50th percentile RQ values (values
shown adjacent to each curves and demarcated by intercepts of the horizontal solid lines) were compared. (C) Left panels show the mean 48h
profiles and right panels show the day and night averages of VO2, VCO2 and energy expenditure (EE, kcal/day/kg0.75) of LF-fed control vs. LF-fed
AOiGHD mice conducted in a single run (n = 5 mice/group). (D) Impact of AOiGHD on day and night activity levels. (E) Impact of AOiGHD on 24h ad
libitum food and water intake. Asterisks indicate values that differ from controls, *, p,0.05, ** p,0.01, and *** p,0.001.
doi:10.1371/journal.pone.0015767.g005
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impacts tissue specific changes in insulin sensitivity, the fact that
glucose levels remained significantly lower in LF and HF-fed
AOiGHD mice up to 2 hours post insulin injection, suggest
hepatic glucose output is decreased in AOiGHD mice, which
would be consistent with an improvement in hepatic insulin
sensitivity.
The reduction in hepatic TG content in HF-fed AOiGHD mice
at first appears in conflict with the reports showing hepatosteatosis
develops in mice with liver-specific knockout of STAT5b [48], a
key mediator of hepatic GH actions, and in mice with liver-specific
knockout of GHR [49]. In the liver-specific GHR knockout mice,
lipid accumulation was associated with a decrease in TG secretion
[49]. However, it should be noted that liver-specific knockout of
GH signaling is associated with low circulating IGF-I leading to a
compensatory rise in GH which in turn serves to breakdown fat,
elevating circulating FFA levels and reducing whole body insulin
sensitivity and glucose clearance. Therefore differences in hepatic
accumulation of lipids in AOiGHD mice, as compared with
hepatic GH resistance mice, may in fact be indirectly mediated by
changes in lipid flux and hepatic insulin signaling. This hypothesis
is supported by the observation that bGH transgenic mice are also
insulin resistant and show reduced hepatic TG secretion [50]. In
addition, it should be noted that developmental hepatic GH
resistance (unlike the AOiGHD model) may impact normal
development of the liver, where GH is critical for normal
hepatocyte proliferation [48]. Therefore it could be argued that
in the hepatic GH resistant mouse models there may be a
disproportionate influx of lipids relative to hepatic mass.
In summary, this report describes the development and
characterization of a unique mouse model of AOiGHD, where
circulating GH levels were selectively reduced but not eliminated.
As summarized in Table 2, these initial investigations reveal that
even partial GHD has a dramatic impact on metabolic function
resulting in improved whole body insulin sensitivity independent of
diet. With excess caloric intake, AOiGHD leads to an increase in
adipose tissue mass, reduced hepatic lipid accumulation, but
deterioration of glucose clearance rates, associated with impaired
insulin output. From these initial observations we might speculate
that the age-related decline in GH may indeed help maintain
healthy metabolic function if nutrient intake is restricted.
However, GHD may contribute to the development of diabetes
in diet-induced obese subjects by limiting insulin output.
Supporting Information
Figure S1 Confirmation that the differences observed in
AOiGHD (DT-treated Cre+/2,DTR+/2) and control (DT-treated
Cre2/2,DTR+/2) mice were due to GH deficiency and not to
genotype. (A) Growth curves, (B) circulating GH, IGF-I, glucose
and insulin, (C) response to insulin tolerance tests (ITT, 1U/kg ip),
(D) 48h respiratory quotient (RQ) profiles, as assessed by indirect
calorimetry. Male mice were provided a standard rodent chow
diet (17% kcal from fat) and were NOT treated with DT. (E)
Tissue weight adjusted by body weight, at 10 months of age. There
were no difference between genotype in all endpoints examined,
where each test was performed at an age similar to those shown for
DT-treated mice fed a standard rodent chow diet. n = 8–10 mice/
genotype.
(PDF)
Figure S2 Impact of DT treatment on the appearance of
pituitary cell types (A, top micrographs), pituitary hormone and
receptor mRNA levels and circulating hormones levels (B, lower
graphs) in Cre+/2,DTR+/2 (AOiGHD) mice, compared to Cre2/
2,DTR+/2 (control) mice. (A) Micrographs - Immunocytochem-
istry for GH, prolactin (PRL), ß-subunit of thyroid stimulating
hormone (TSH), ß-subunit of luteinizing hormone (LH) and
adrenocorticotropic hormone (ACTH) performed 2 months post
DT treatment, in chow fed mice. AOiGHD mice have fewer GH-
immunopositive cells which are more intensely stained, while the
appearance of the other pituitary cell types were not diminished
and in fact appear more concentrated; a situation that is expected
if somatotropes, which normally represent 50% of the pituitary cell
population, were removed by DT treatment. (B) Graphics – In
samples taken from high-fat (HF) and low-fat (LF) fed mice at 12
months of age, somatotrope specific transcripts (GH, GH releasing
hormone receptor [GHRH-R] and ghrelin receptor [GHS-R])
were reduced in AOiGHD mice, while PRL mRNA levels were
only modestly reduced, but did not lead to a reduction in
circulating PRL levels, compared to controls. In contrast,
transcripts associated with thyrotropes, gonadotropes and cortico-
tropes were increased, but this did not alter associated circulating
hormones (also refer to Table 1 in text). When interpreting the
changes in the pituitary mRNA levels, it would be anticipated that
Table 2. Metabolic changes observed in AOiGHD mice.
Level of Caloric
Intake*
Low Moderate High
Body composition
Body Weight (g) 2 2 Q
Lean Mass (NMR) nd Q nd
Fat Mass (NMR) nd q nd
Fat Depot Weight (g) 2 q q
Circulating Nutrients (fed/fasted)
Triglycerides 2/2 nd 2/2
Cholesterol 2/2 nd 2/2
Free Fatty Acids 2/2 nd 2/2
Glucose 2/2 Q/nd 2/2
Liver
Weight (g) 2 Q Q
TG content 2 Q Q
IGF-I (ng/ml) Q Q Q
IGF-I mRNA Q Q Q
Glucose Homeostasis
Respiratory Quotient q nd q
Insulin Sensitivity (ITT) q q q
Insulin fed/fasted (ng/ml) Q/Q Q/nd Q/Q
Pancreatic Insulin mRNA Q nd Q
Glucose Clearance (GTT) 2 2 Q
*, Low (low-fat diet, 10% calories from fat), Moderate (standard chow diet, 17%
calories from fat), High (high-fat diet, 45% calories from fat).
Consistent across diets, male AOiGHD mice are more insulin sensitive, with
lower circulating levels of IGF-I and insulin. As caloric intake increases adipose
mass increases and liver weight decreases, where the later is associated with
reduced triglyceride content (TG). Despite, improved insulin sensitivity, glucose
clearance deteriorates in high-fat fed AOiGHD mice. It is hypothesized that this
is due to inappropriate pancreatic insulin production, which remains to be
tested. Symbols indicate increases (q), decreases (Q), or no change (2) in
AOiGHD mice, relative to GH-intact controls. nd, not determined; NMR, whole
body nuclear magnetic resonance; ITT, insulin tolerance test; GTT, glucose
tolerance test.
doi:10.1371/journal.pone.0015767.t002
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the relative expression of hormones produced by non-somato-
tropes would double if DT-mediated destruction was limited to the
majority of somatotropes, which normally make up 50% of all cells
in the male pituitary gland. Indeed this was the case for ACTH,
LH and TSH mRNAs. However, PRL mRNA levels were the
same in LF and modestly reduced in HF conditions in AOiGHD
mice compared to controls. This may indicate some lactotropes
were destroyed by DT-treatment. An alternative (or additional)
explanation is that the reduced levels of IGF-I are responsible for
reduced PRL mRNA levels, where IGF-I has been shown to be
required for maximal PRL expression. The reduced IGF-I may in
fact be a dominant player in reduced PRL mRNA in AOiGHD
since DT did not directly suppress PRL mRNA levels in vitro,
while having a profound impact on GH mRNA levels, as shown in
Figure 1G, in the main text. Asterisks indicate a significant
difference between controls and AOiGHD, within diet (p,0.05),
as assessed by 2-way ANOVA, followed by Newman Keul’s post-
hoc tests for group comparisons. Also, HF feeding did have a
significant inhibitory impact on GH, GHRH-R, GHS-R and
circulating testosterone levels, independent of GH status (a,
p,0.05).
(PDF)
Figure S3 Hemotoxylin:Eosin stained paraffin embedded liver
sections from AOiGHD and GH-intact controls. Mice were fed a
standard rodent chow diet (17% kcal from fat) and tissues collected
at 10 months of age (7 months after DT treatment). In AOiGHD
hepatocytes, there is less open (unstained) area, as compared to
GH-intact controls, consistent with reduced hepatic triglyceride
levels in high-fat fed AOiGHD mice (shown in Fig. 3 in main body
of the text).
(PDF)
Figure S4 Comparison of food and water intake (A), kcal
consumed (B) and activity levels of control mice (GH-intact) fed
either a low fat (LF) or high fat (HF) diet. *, p,0.05 and
** p,0.01.
(PDF)
Table S1 Fertility endpoints in AOiGHD mice, compared to
wildtype (WT) mice in a C57Bl/6J background *All 5 female
AOiGHD mice successfully cared for their litters until weaning
(d21). { Similar data was obtained from C57Bl/6J females housed
at the University of Cordoba, Spain (days to conception 6.162.4;
pups/litter 5.160.4 - Raul M. Luque and Jose Cordoba,
unpublished data). Jackson Laboratories report C57Bl/6J mice
are ‘‘good’’ breeders with 3–7 pups/litter http://jaxmice.jax.org/
strain/000664.html
(PDF)
Table S2 Impact of AOiGHD and diet on circulating
metabolites. Fed and fasted samples were taken at t0 of ITT
and GTT, respectively, where GTT was performed 3 weeks after
ITT, on control and AOiGHD mice fed a low-fat (LF) or high-fat
(HF) diet. Given the age differences between fed and fasted
sampling, the impact of GH-status and diet were made within
feeding status (ie. fed or fasted), using 2-way ANOVA, followed by
Newman’s Keuls’ test for post-hoc comparisons. GH-status, within
diet, did not alter the endpoints measured, however, high fat
feeding increased circulating glucose and cholesterol levels as
compared to LF-fed controls, independent of GH-status, under
both fed and fasted conditions (*, p,0.05).
(PDF)
Table S3 PCR primer sets, positions relative Genbank sequence
provided and products sizes.
(PDF)
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